Clearpoint Neuro Inc

NASDAQ CLPT

Data sourced from

and

Download Data

Clearpoint Neuro Inc Liabilities to Equity Ratio 3 year CAGR for the year ending December 31, 2023: -55.44%

Clearpoint Neuro Inc Liabilities to Equity Ratio 3 year CAGR is -55.44% for the year ending December 31, 2023, a -73.53% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Clearpoint Neuro Inc Liabilities to Equity Ratio for the year ending December 31, 2022 was 0.50, a 46.51% change year over year.
Clearpoint Neuro Inc Liabilities to Equity Ratio for the year ending December 31, 2021 was 0.34, a -97.00% change year over year.
Clearpoint Neuro Inc Liabilities to Equity Ratio for the year ending December 31, 2020 was 11.47, a 616.75% change year over year.
Clearpoint Neuro Inc Liabilities to Equity Ratio for the year ending December 31, 2019 was 1.60, a -61.90% change year over year.

NASDAQ: CLPT

Clearpoint Neuro Inc

CEO	Mr. Joseph Michael Burnett
IPO Date	Feb. 12, 2020
Location	United States
Headquarters	120 S. Sierra Avenue, Solana Beach, CA, United States, 92075
Employees	107
Sector	Healthcare
Industry	Medical devices

Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Key trends